Shaun Moon, DO
Family Medicine · Swartz Creek, MINPI 1942614953
Payments from drug & device makers
Across 246 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$602
- Pfizer$520
- GSK$455
- AbbVie$308
- Astellas Pharma US Inc$247
- Johnson & Johnson$192
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,036100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $602 |
| Pfizer | 37 | $520 |
| GSK | 24 | $455 |
| AbbVie | 19 | $308 |
| Astellas Pharma US Inc | 13 | $247 |
| Johnson & Johnson | 10 | $192 |
| Merck | 11 | $168 |
| Amgen | 9 | $155 |
| Lilly USA, LLC | 10 | $145 |
| Seqirus USA Inc | 6 | $123 |
| Novartis | 7 | $117 |
| Otsuka America Pharmaceutical, Inc. | 6 | $104 |
| AstraZeneca(2 entities) | 6 | $89 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $85 |
| Boehringer Ingelheim | 6 | $85 |
| Exact Sciences | 4 | $62 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $50 |
| Amarin Pharma, Inc. | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Bayer | 2 | $36 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Daiichi Sankyo Inc. | 2 | $29 |
| Alkermes, Inc. | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Gilead | 2 | $25 |
| Abbott | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Corium, LLC | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| UCB, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
| Hologic Sales And Service, LLC | 1 | $11 |
How this compares
$4,036 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 200 | $207,250 |
| TrulicityDulaglutide | 105 | $131,366 |
| MounjaroTirzepatide | 69 | $70,905 |
| JardianceEmpagliflozin | 36 | $57,919 |
| OzempicSemaglutide | 44 | $55,255 |
| RybelsusSemaglutide | 38 | $45,415 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $40,167 |
| FarxigaDapagliflozin Propanediol | 18 | $21,830 |
| RexultiBrexpiprazole | 14 | $19,575 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $19,570 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 88 | $19,433 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 61 | $19,213 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $18,088 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $13,276 |
| Spiriva HandihalerTiotropium Bromide | 15 | $10,547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $520 | $226,463261 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $145 | $202,270174 claims |
| Novo NordiskOzempic, Rybelsus | $602 | $100,67082 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix, Breo Ellipta | $455 | $97,257190 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $85 | $63,46948 claims |
| AstraZenecaFarxiga | $89 | $21,83018 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $104 | $19,57514 claims |
| MerckJanuvia | $168 | $10,10511 claims |
| Johnson & JohnsonInvokana | $192 | $8,06313 claims |
| AbbVieSynthroid | $308 | $3,05545 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Swartz Creek
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.